Faron Pharmaceuticals Oy (FRA:4FR) LT-Debt-to-Total-Asset: 0.83 (As of Dec. 2025)


FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
21 GF Score
Price €0.51
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset?

Faron Pharmaceuticals Oy FRA:4FR -1.37% 21 LT-Debt-to-Total-Asset is 0.83 as of Dec. 2025. GuruFocus rates FRA:4FR with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Faron Pharmaceuticals Oy's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.83.

Faron Pharmaceuticals Oy's long-term debt to total assets ratio increased from Dec. 2024 (0.66) to Dec. 2025 (0.83). It may suggest that Faron Pharmaceuticals Oy is progressively becoming more dependent on debt to grow their business.

Faron Pharmaceuticals Oy  (FRA:4FR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset Related Terms

Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 1.00 0.93 0.66 0.83

Faron Pharmaceuticals Oy Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.25 0.66 1.32 0.83
FRA:4FR
21GF Score
Faron Pharmaceuticals Oy FRA:4FR
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy LT-Debt-to-Total-Asset Calculation

Faron Pharmaceuticals Oy's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=14.279/17.172
=

Faron Pharmaceuticals Oy's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=14.279/17.172
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.83 mean?
Faron Pharmaceuticals Oy (FRA:4FR) has a LT-Debt-to-Total-Asset of 0.83 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's LT-Debt-to-Total-Asset too high?
Faron Pharmaceuticals Oy's current LT-Debt-to-Total-Asset is 0.83. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Faron Pharmaceuticals Oy's LT-Debt-to-Total-Asset of 0.83 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current LT-Debt-to-Total-Asset is 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current LT-Debt-to-Total-Asset of 0.83. The current LT-Debt-to-Total-Asset is 0.83. Faron Pharmaceuticals Oy's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current LT-Debt-to-Total-Asset is 0.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
21GF Score

Get the complete analysis for FRA:4FR

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price